HPS2-THRIVE Trial

Study / Research

The Heart Protection Study 2 to THRVIVE trial, a large cardiovascular outcomes trial that showed no cardiovascular benefits from niacin therapy.

Mentioned in 1 video

Videos Mentioning HPS2-THRIVE Trial

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

The Heart Protection Study 2 to THRVIVE trial, a large cardiovascular outcomes trial that showed no cardiovascular benefits from niacin therapy.